Primary Site >> Colorectal Cancer
Gene >> ZHX2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Activation of human c-raf-1 by replacing the N-terminal region with different sequences. PMID: 2955285 |
Ref: Enhanced expression of oncogene-encoded mRNA in a rat model of colon cancer. PMID: 2012108 |
Ref: Detection of transforming oncogenes in rat colon tumors induced by direct perfusion with N-methyl-N-nitrosourea. PMID: 1730134 |
Ref: Multiple polyps of esophagus, stomach, colon, and rectum accompanying rectal cancer in a patient with constitutional chromosomal inversion. PMID: 8431846 |
Ref: The neurotensin gene is a downstream target for Ras activation. PMID: 7769122 Ref: Options for screening for colorectal cancer in the Royal Air Force: a cost-effectiveness evaluation. PMID: 8568748 |
Ref: Suppression of a human colon cancer cell line by introduction of an exogenous NF1 gene. PMID: 8665528 |
Ref: Src-mediated activation of the human neurotensin/neuromedin N promoter. PMID: 9288121 Ref: Suppression of serum-induced c-jun expression by activated Ki-ras in human colon cancer cells. PMID: 12503187 |
Ref: Abrogation of c-Raf expression induces apoptosis in tumor cells. PMID: 9583688 Ref: Oncogenic ras induces gastrin gene expression in colon cancer. PMID: 9797369 |
Ref: Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells. PMID: 10086335 Ref: XR3054, structurally related to limonene, is a novel inhibitor of farnesyl protein transferase. PMID: 10533487 |
Ref: [Deregulation of intracellular signal pathways in colorectal carcinoma]. PMID: 10929640 |
Ref: Upregulation of non-mutated H-ras and its upstream and downstream signaling proteins in colorectal cancer. PMID: 11605075 |
Ref: Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. PMID: 11773051 Ref: Phorbol 12-myristate 13-acetate up-regulates the transcription of MUC2 intestinal mucin via Ras, ERK, and NF-kappa B. PMID: 12077118 Ref: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. PMID: 12198537 Ref: Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis. PMID: 12359742 Ref: Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. PMID: 12438234 Ref: The role of Raf kinases in malignant transformation. PMID: 14987392 |
Ref: Raf proteins and cancer: B-Raf is identified as a mutational target. PMID: 12781369 Ref: BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. PMID: 12941809 Ref: BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. PMID: 14668801 Ref: Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. PMID: 14678966 |
Ref: No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract. PMID: 14654916 Ref: Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. PMID: 14695993 Ref: Prostaglandin E2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells. PMID: 14742435 Ref: Regulation of phorbol ester-mediated TRAF1 induction in human colon cancer cells through a PKC/RAF/ERK/NF-kappaB-dependent pathway. PMID: 14981539 Ref: In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. PMID: 14991899 Ref: RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers. PMID: 15118616 Ref: Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular tra PMID: 15150094 Ref: Both BRAF and KRAS mutations are rare in colorectal carcinomas from patients with hereditary nonpolyposis colorectal cancer. PMID: 15194222 Ref: Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase. PMID: 15210862 Ref: Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. PMID: 15294875 Ref: BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. PMID: 15342696 Ref: Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas. PMID: 15513360 Ref: Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. PMID: 15542810 |
Ref: Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. PMID: 15532096 Ref: DRO1, a gene down-regulated by oncogenes, mediates growth inhibition in colon and pancreatic cancer cells. PMID: 15563452 Ref: The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. PMID: 15655409 Ref: Mutational analysis of the ARAF gene in human cancers. PMID: 15676015 Ref: Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma. PMID: 15704157 Ref: BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. PMID: 15729718 Ref: Transformation of immortalized colorectal crypt cells by microcystin involving constitutive activation of Akt and MAPK cascade. PMID: 15774489 Ref: Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells. PMID: 15930183 Ref: Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. PMID: 16197622 Ref: Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation. PMID: 16294035 |
Ref: Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K-ras mutations. PMID: 16219636 Ref: Glycogen synthase kinase-3 is a negative regulator of extracellular signal-regulated kinase. PMID: 16278684 Ref: BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. PMID: 16403224 Ref: Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations. PMID: 16413100 Ref: Activation of Ras/Raf protects cells from melanoma differentiation-associated gene-5-induced apoptosis. PMID: 16575407 Ref: EGF receptor-related protein (ERRP) inhibits invasion of colon cancer cells and tubule formation by endothelial cells in vitro. PMID: 16619503 Ref: Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. PMID: 16959882 Ref: Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology. PMID: 17065421 Ref: Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. PMID: 17179102 Ref: BRAF mutations in papillary thyroid carcinoma. PMID: 17201587 |
Ref: In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors. PMID: 17363484 Ref: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. PMID: 17363584 Ref: Highly conserved sequence of exon 15 BRAF gene and KRAS codon 12 mutation among Greek patients with colorectal cancer. PMID: 17393356 Ref: Induction of differentiation of colon cancer cells by combined inhibition of kinases and histone deacetylase. PMID: 17465197 Ref: Inhibition of colon cancer cell growth and antioxidant activity of bioactive compounds from Poncirus trifoliata (L.) Raf. PMID: 17512744 Ref: Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. PMID: 17631144 Ref: [Effects of extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway activation on proliferation and cell cycle associated genes in human colon cancer cells]. PMID: 17650425 Ref: Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth. PMID: 17699719 Ref: Molecular analysis of colorectal cancer tumors from patients with mismatch repair proficient hereditary nonpolyposis colorectal cancer suggests novel carcinogenic pathways. PMID: 17908962 Ref: Therapeutic strategies for targeting BRAF in human cancer. PMID: 18473997 |
Ref: Phorbol ester up-regulates phospholipase D1 but not phospholipase D2 expression through a PKC/Ras/ERK/NFkappaB-dependent pathway and enhances matrix metalloproteinase-9 secretion in colon cancer cells. PMID: 18084005 Ref: Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. PMID: 18372904 Ref: DxS Ltd. PMID: 18384259 Ref: Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells. PMID: 18413805 Ref: Individual tumorigenesis pathways of sporadic colorectal adenocarcinomas are associated with the biological behavior of tumors. PMID: 18422752 Ref: Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. PMID: 18451217 Ref: Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6. PMID: 18454176 Ref: Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients. PMID: 18575712 Ref: RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A. PMID: 18592002 Ref: B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival. PMID: 18602919 Ref: [The RAS paradox of the EGFR-targeted therapy in colorectal cancer]. PMID: 18640895 Ref: Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. PMID: 18695262 Ref: Reciprocal regulation of extracellular signal regulated kinase 1/2 and mitogen activated protein kinase phosphatase-3. PMID: 18771677 Ref: Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. PMID: 18806830 Ref: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. PMID: 18852116 |
Ref: Tumour cell survival signalling by the ERK1/2 pathway. PMID: 18846109 Ref: TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway. PMID: 19208363 Ref: Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors. PMID: 19362830 Ref: KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue. PMID: 19368524 Ref: KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. PMID: 19372556 Ref: Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated B-Raf. PMID: 19378335 Ref: Tax1 enhances cancer cell proliferation via Ras-Raf-MEK-ERK signaling pathway. PMID: 19472191 Ref: Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer. PMID: 19474002 Ref: Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PMID: 19492075 Ref: CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. PMID: 19509149 Ref: Chemoresponsiveness associated with canonical molecular changes in colorectal adenocarcinomas. PMID: 19661324 Ref: Up-regulation of Kruppel-like factor 5 in pancreatic cancer is promoted by interleukin-1beta signaling and hypoxia-inducible factor-1alpha. PMID: 19671674 Ref: A gene marker panel covering the Wnt and the Ras-Raf-MEK-MAPK signalling pathways allows to detect gene mutations in 80% of early (UICC I) colon cancer stages in humans. PMID: 19679059 Ref: Down-regulation of Cdx2 in colorectal carcinoma cells by the Raf-MEK-ERK 1/2 pathway. PMID: 19686845 Ref: Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells. PMID: 19700418 Ref: Effects of lysophosphatidic acid on human colon cancer cells and its mechanisms of action. PMID: 19777613 Ref: Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer. PMID: 19917537 Ref: KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. PMID: 19934290 Ref: The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis. PMID: 20015382 Ref: The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. PMID: 20130433 Ref: [Biomarkers and anti-EGFR therapies for KRAS wild-type tumors in metastatic colorectal cancer patients]. PMID: 20432670 |
Ref: The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. PMID: 20067946 Ref: Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients. PMID: 20088793 Ref: TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status. PMID: 20146801 Ref: Growth and invasion of sporadic colorectal adenocarcinomas in terms of genetic change. PMID: 20191032 Ref: Bile acid regulates MUC2 transcription in colon cancer cells via positive EGFR/PKC/Ras/ERK/CREB, PI3K/Akt/IkappaB/NF-kappaB and p38/MSK1/CREB pathways and negative JNK/c-Jun/AP-1 pathway. PMID: 20198339 Ref: The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE(2) signalling in colorectal adenoma cells. PMID: 20348947 Ref: Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells. PMID: 20406951 Ref: PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. PMID: 20496265 Ref: Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. PMID: 20708155 Ref: Raf kinase inhibitor protein suppresses nuclear factor-kappaB-dependent cancer cell invasion through negative regulation of matrix metalloproteinase expression. PMID: 20855151 Ref: GABA-receptor agonist, propofol inhibits invasion of colon carcinoma cells. PMID: 20888181 Ref: Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. PMID: 20923857 Ref: Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? PMID: 21129611 Ref: Mutation analysis of BRAF exon 15 and KRAS codons 12 and 13 in Moroccan patients with colorectal cancer. PMID: 21161938 Ref: Detection of up to 65% of Precancerous Lesions of the Human Colon and Rectum by Mutation Analysis of APC, K-Ras, B-Raf and CTNNB1. PMID: 24212608 |
Ref: Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. PMID: 20473860 Ref: KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. PMID: 21163703 Ref: Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. PMID: 21233242 Ref: B-Raf mutations, microsatellite instability and p53 protein expression in sporadic basal cell carcinomas. PMID: 21274671 Ref: The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. PMID: 21464044 Ref: Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. PMID: 21516509 Ref: KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing. PMID: 21575616 Ref: Clinical features and molecular alterations of traditional serrated adenoma in sporadic colorectal carcinogenesis. PMID: 21615873 Ref: An Update on the Biology of RAS/RAF Mutations in Colorectal Cancer. PMID: 21625338 Ref: Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. PMID: 21705440 Ref: Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. PMID: 21712828 Ref: [Predictive biomarkers of anti-EGFR monoclonal anti-body in colorectal cancer]. PMID: 21772090 Ref: PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PMID: 21829508 Ref: The GLI genes as the molecular switch in disrupting Hedgehog signaling in colon cancer. PMID: 21860067 Ref: [Tm analysis method using a quenching probe is a simple and rapid way to simultaneously detect KRAS and BRAF mutations]. PMID: 21942085 Ref: BRAF mutations in advanced cancers: clinical characteristics and outcomes. PMID: 22039425 Ref: Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. PMID: 22174910 |
Ref: MicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression. PMID: 21860426 Ref: Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? PMID: 22043994 Ref: Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. PMID: 22147942 Ref: Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. PMID: 22169769 Ref: Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. PMID: 22180495 Ref: Real-time PCR-based analysis of BRAF V600E mutation in low and intermediate grade lymphomas confirms frequent occurrence in hairy cell leukaemia. PMID: 22246856 Ref: Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling. PMID: 22260668 Ref: The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. PMID: 22261800 Ref: A new model for raf kinase inhibitory protein induced chemotherapeutic resistance. PMID: 22279539 Ref: CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity. PMID: 22319199 Ref: MicroRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells. PMID: 22322462 Ref: ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics. PMID: 22376079 Ref: Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. PMID: 22392911 Ref: A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. PMID: 22421192 Ref: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. PMID: 22448344 Ref: Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside. PMID: 22471666 Ref: Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. PMID: 22490361 Ref: Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer. PMID: 22496204 Ref: Ras signaling pathway in the chemopreventive action of different ratios of fish oil and corn oil in experimentally induced colon carcinogenesis. PMID: 22519408 Ref: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. PMID: 22773810 Ref: Differential involvement of RalA and RalB in colorectal cancer. PMID: 22790202 Ref: BAY61-3606 affects the viability of colon cancer cells in a genotype-directed manner. PMID: 22815993 Ref: PAQR3 plays a suppressive role in the tumorigenesis of colorectal cancers. PMID: 22828136 Ref: K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy. PMID: 22909976 Ref: Combination therapy targeting Raf-1 and MEK causes apoptosis of HCT116 colon cancer cells. PMID: 22922669 Ref: High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues. PMID: 22938585 Ref: Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules. PMID: 23033949 Ref: A LIN28B polymorphism predicts for colon cancer survival. PMID: 23052130 Ref: MUC5AC/beta-catenin expression and KRAS gene alteration in laterally spreading colorectal tumors. PMID: 23112547 Ref: [Predictive biomarkers for anti-EGFR antibodies]. PMID: 23152013 Ref: [KRAS and BRAF gene mutations in correlation with clinicopathologic features of colorectal carcinoma in Chinese]. PMID: 23157824 Ref: [Anti-EGFR antibody therapy for colorectal cancer]. PMID: 23259389 Ref: Alternative dosing of dual PI3K and MEK inhibition in cancer therapy. PMID: 23259591 Ref: Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients. PMID: 23317280 Ref: (18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors. PMID: 23372439 |
Ref: Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy. PMID: 22983756 Ref: Overexpression of galectin-3 enhances migration of colon cancer cells related to activation of the K-Ras-Raf-Erk1/2 pathway. PMID: 23015305 Ref: Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome. PMID: 23158210 Ref: Raf and PI3K are the molecular targets for the anti-metastatic effect of luteolin. PMID: 23172826 Ref: Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling. PMID: 23233484 Ref: Alternative splicing of BRAF transcripts and characterization of C-terminally truncated B-Raf isoforms in colorectal cancer. PMID: 23354951 Ref: Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. PMID: 23365119 Ref: Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. PMID: 23374602 Ref: High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. PMID: 23548132 Ref: APC loss-induced intestinal tumorigenesis in Drosophila: Roles of Ras in Wnt signaling activation and tumor progression. PMID: 23570874 Ref: [Biomarkers in solid tumors]. PMID: 23573523 Ref: Critical appraisal of the use of regorafenib in the management of colorectal cancer. PMID: 23610528 Ref: Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. PMID: 23629727 Ref: In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. PMID: 23630290 Ref: Phase I/II RAF kinase inhibitors in cancer therapy. PMID: 23642225 Ref: Aspirin use and risk of colorectal cancer according to BRAF mutation status. PMID: 23800934 Ref: Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis. PMID: 23934607 Ref: Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. PMID: 23938455 Ref: Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients. PMID: 23943423 Ref: Molecular alterations of Ras-Raf-mitogen-activated protein kinase and phosphatidylinositol 3-kinase-Akt signaling pathways in colorectal cancers from a tertiary hospital at Kuala Lumpur, Malaysia. PMID: 23992303 Ref: Multi-kinase modulation for colon cancer therapy. PMID: 24025253 Ref: Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. PMID: 24071017 Ref: B-Raf mutation: a key player in molecular biology of cancer. PMID: 24161954 Ref: Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors. PMID: 24259629 Ref: Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF. PMID: 24298448 Ref: Not all antibodies are equal. PMID: 24317328 Ref: The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. PMID: 24330663 Ref: Analysis of the anatomic subsites, gender and age in unresectable advanced colorectal carcinomas in Tochigi, Japan suggests a shift in location towards the right side colon in elderly patients treated with cetuximab. PMID: 24649163 Ref: Clinical implications of BRAF mutation test in colorectal cancer. PMID: 24834238 Ref: A two-hybrid approach to identify inhibitors of the RAS-RAF interaction. PMID: 25033807 Ref: Discovery of small-molecule Ras inhibitors that display antitumor activity by interfering with Ras.GTP-effector interaction. PMID: 25034098 |
Ref: Personalizing therapy for colorectal cancer. PMID: 24025538 Ref: CRNDE, a long non-coding RNA responsive to insulin/IGF signaling, regulates genes involved in central metabolism. PMID: 24184209 Ref: The ErbB/HER family of protein-tyrosine kinases and cancer. PMID: 24269963 Ref: Clinical significance of RKIP mRNA expression in non-small cell lung cancer. PMID: 24420151 Ref: When to screen and not to screen. PMID: 24424112 Ref: Is biomarker research advancing in the era of personalized medicine for head and neck cancer? PMID: 24442754 Ref: Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer. PMID: 24458108 Ref: Paris saponin VII inhibits growth of colorectal cancer cells through Ras signaling pathway. PMID: 24462916 Ref: Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status. PMID: 24495750 Ref: Mutational analysis and clinical correlation of metastatic colorectal cancer. PMID: 24500602 Ref: PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice. PMID: 24530606 Ref: KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model. PMID: 24558511 Ref: Identification and optimization of new dual inhibitors of B-Raf and epidermal growth factor receptor kinases for overcoming resistance against vemurafenib. PMID: 24588073 Ref: [Perspective of personalized (precise) cancer therapy based on predictive biomarkers]. PMID: 24597345 Ref: ZIC1 is a putative tumor suppressor in thyroid cancer by modulating major signaling pathways and transcription factor FOXO3a. PMID: 24684457 Ref: Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. PMID: 24691006 Ref: Vemurafenib. PMID: 24756795 Ref: The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies. PMID: 24758538 Ref: Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis. PMID: 24763611 Ref: Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer. PMID: 24778007 Ref: Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. PMID: 24812410 Ref: Ras in digestive oncology: from molecular biology to clinical implications. PMID: 24849046 Ref: Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells. PMID: 24885690 Ref: Acquired resistance to EGFR-targeted therapies in colorectal cancer. PMID: 24913799 Ref: The BRAF mutation is associated with the prognosis in colorectal cancer. PMID: 24942334 Ref: Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. PMID: 24947927 Ref: Phloroglucinol induces apoptosis through the regulation of insulin-like growth factor 1 receptor signaling pathways in human colon cancer HT-29 cells. PMID: 24970012 Ref: The study of a novel sorafenib derivative HLC-080 as an antitumor agent. PMID: 25004130 Ref: Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. PMID: 25057166 Ref: Development of siRNA payloads to target KRAS-mutant cancer. PMID: 25100204 Ref: Association between raf kinase inhibitor protein loss and prognosis in cancers of the digestive system: a meta-analysis. PMID: 25171481 Ref: Thymoquinone-induced conformational changes of PAK1 interrupt prosurvival MEK-ERK signaling in colorectal cancer. PMID: 25174975 Ref: BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. PMID: 25367198 Ref: Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis. PMID: 25427581 Ref: Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer. PMID: 25444464 Ref: High frequency of BRAF proto-oncogene hot spot mutation V600E in cohort of colorectal cancer patients from Ahvaz City, southwest Iran. PMID: 25911848 |
Ref: A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity. PMID: 24469059 Ref: Colorectal serrated pathway cancers and precursors. PMID: 25263173 Ref: B-RAF mutation and accumulated gene methylation in aberrant crypt foci (ACF), sessile serrated adenoma/polyp (SSA/P) and cancer in SSA/P. PMID: 25314065 Ref: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. PMID: 25322874 Ref: MicroRNA-455 inhibits proliferation and invasion of colorectal cancer by targeting RAF proto-oncogene serine/threonine-protein kinase. PMID: 25355599 Ref: B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells. PMID: 25381152 Ref: Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. PMID: 25589621 Ref: Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer. PMID: 25637165 Ref: Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. PMID: 25673644 Ref: AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants. PMID: 25714871 Ref: Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas. PMID: 25785246 Ref: Methionine adenosyltransferase 2B-GIT1 complex serves as a scaffold to regulate Ras/Raf/MEK1/2 activity in human liver and colon cancer cells. PMID: 25794709 Ref: Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9. PMID: 25805818 Ref: Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. PMID: 25838391 Ref: Design, synthesis, in vitro antiproliferative evaluation, and kinase inhibitory effects of a new series of imidazo[2,1-b]thiazole derivatives. PMID: 25841200 Ref: Old Habits Die Hard: Addiction of BRAF-Mutant Cancer Cells to MAP Kinase Signaling. PMID: 25847954 Ref: A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer. PMID: 25861837 Ref: Preclinical analysis of the anti-tumor and anti-metastatic effects of Raf265 on colon cancer cells and CD26(+) cancer stem cells in colorectal carcinoma. PMID: 25884645 Ref: HGUE-C-1 is an atypical and novel colon carcinoma cell line. PMID: 25885658 Ref: Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers. PMID: 25920435 Ref: KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells. PMID: 25933688 Ref: N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors. PMID: 26005530 Ref: Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. PMID: 26027741 Ref: Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancer. PMID: 26033452 Ref: Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation. PMID: 26058013 Ref: Rectal and colon cancer: Not just a different anatomic site. PMID: 26145760 Ref: BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. PMID: 26208524 Ref: Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. PMID: 26299805 Ref: Rhomboid domain containing 1 promotes colorectal cancer growth through activation of the EGFR signalling pathway. PMID: 26300397 Ref: Probing a 3,4'-bis-guanidinium diaryl derivative as an allosteric inhibitor of the Ras pathway. PMID: 26318998 Ref: Expression of tumor-related Rac1b antagonizes B-Raf-induced senescence in colorectal cells. PMID: 26341689 Ref: Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors. PMID: 26351322 Ref: Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer. PMID: 26427914 Ref: Global gene expression profiling analysis reveals reduction of stemness after B-RAF inhibition in colorectal cancer cell lines. PMID: 26484206 Ref: [A Case of Serrated Polyposis Syndrome with Early Colon Cancer]. PMID: 26805315 Ref: The molecular background of mucinous carcinoma beyond MUC2. PMID: 27499889 |
Ref: RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. PMID: 26350096 Ref: Involvement of Notch-1 in Resistance to Regorafenib in Colon Cancer Cells. PMID: 26419617 Ref: Past, Present, and Future of Targeting Ras for Cancer Therapies. PMID: 26423695 Ref: Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside. PMID: 26616508 Ref: Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. PMID: 26660078 Ref: A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. PMID: 26666244 Ref: Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice. PMID: 26774139 Ref: Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases. PMID: 26797410 Ref: BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells. PMID: 26802026 Ref: Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. PMID: 26861740 Ref: GeneGazer: A Toolkit Integrating Two Pipelines for Personalized Profiling and Biosignature Identification. PMID: 26912804 Ref: A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation. PMID: 26916115 Ref: Impact of Cellular Genetic Make-up on Colorectal Cancer Cell Lines Response to Ellagic Acid: Implications of Small Interfering RNA. PMID: 26925673 Ref: PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor. PMID: 26933175 Ref: ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models: efficiency of DAT1 in Ras-Raf mutated cells. PMID: 26956619 Ref: Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation. PMID: 26959608 Ref: Mechanistic study of the anti-cancer effect of Gynostemma pentaphyllum saponins in the Apc(Min/+) mouse model. PMID: 26970558 Ref: The association of clinicopathological features and survival in colorectal cancer patients with kras mutation status. PMID: 27072218 Ref: MicroRNA Expression Signatures Associated With BRAF-Mutated Versus KRAS-Mutated Colorectal Cancers. PMID: 27082577 Ref: miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling. PMID: 27095166 Ref: BRD7: a novel tumor suppressor gene in different cancers. PMID: 27158366 Ref: Blockage of Autophagy Rescues the Dual PI3K/mTOR Inhibitor BEZ235-induced Growth Inhibition of Colorectal Cancer Cells. PMID: 27294206 Ref: Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations. PMID: 27308562 Ref: BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells. PMID: 27351224 Ref: Challenging a dogma: co-mutations exist in MAPK pathway genes in colorectal cancer. PMID: 27401719 Ref: Determination of a novel B-Raf(V600E) and EGFR dual inhibitor in rat plasma by HPLC-MS/MS and its application in a pharmacokinetic study. PMID: 27423011 Ref: Sur8 mediates tumorigenesis and metastasis in colorectal cancer. PMID: 27469030 Ref: Specific inhibition of p110alpha subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers. PMID: 27602501 Ref: Current understanding concerning intestinal stem cells. PMID: 27610020 Ref: MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling. PMID: 27655129 Ref: Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. PMID: 27682134 Ref: 6-C-(E-phenylethenyl)naringenin induces cell growth inhibition and cytoprotective autophagy in colon cancer cells. PMID: 27710830 Ref: Impaired coordination between signaling pathways is revealed in human colorectal cancer using single-cell mass cytometry of archival tissue blocks. PMID: 27729552 Ref: [Research progress of serrated polyposis syndrome]. PMID: 27781259 Ref: Personalized oncogenomics in the management of gastrointestinal carcinomas-early experiences from a pilot study. PMID: 28050146 Ref: [A Systematic Analysis of Oncogene and Tumor Suppressor Genes for Panitumumab-Resistant Rectal Cancer with Wild RAS Gene - A Case Report]. PMID: 28133295 Ref: [A Case of Metastatic Colorectal Cancer with HER2 Overexpression/Amplification]. PMID: 28133304 |
Ref: FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. PMID: 27399335 Ref: The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer. PMID: 27678457 Ref: EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer. PMID: 27879995 Ref: FOXD3 is a tumor suppressor of colon cancer by inhibiting EGFR-Ras-Raf-MEK-ERK signal pathway. PMID: 27926503 Ref: LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer. PMID: 27999210 Ref: Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor. PMID: 28011498 Ref: Co-targeting translation and proteasome rapidly kills colon cancer cells with mutant RAS/RAF via ER stress. PMID: 28030835 Ref: Hepatocyte growth factor/MET in cancer progression and biomarker discovery. PMID: 28064454 Ref: Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. PMID: 28073102 Ref: A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. PMID: 28152546 Ref: Comparative Study of Mutations in Single Nucleotide Polymorphism Loci of KRAS and BRAF Genes in Patients Who Underwent Screening Colonoscopy, With and Without Premalignant Intestinal Polyps. PMID: 28179313 Ref: Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. PMID: 28184012 Ref: Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. PMID: 28186126 Ref: Perioperative bevacizumab improves survival following lung metastasectomy for colorectal cancer in patients harbouring v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue exon 2 codon 12 mutationsdagger. PMID: 28186237 Ref: Time-resolved Phosphoproteome Analysis of Paradoxical RAF Activation Reveals Novel Targets of ERK. PMID: 28188228 Ref: Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study. PMID: 28302530 Ref: Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer. PMID: 28323034 Ref: Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance. PMID: 28368067 Ref: The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer. PMID: 28378527 Ref: Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer. PMID: 28405764 Ref: Molecular Testing to Optimize and Personalize Decision Making in the Management of Colorectal Cancer. PMID: 28412781 Ref: Downregulation of RASAL2 promotes the proliferation, epithelial-mesenchymal transition and metastasis of colorectal cancer cells. PMID: 28454265 Ref: ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. PMID: 28465216 Ref: AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes. PMID: 28536078 Ref: Colorectal cancer in cases of multiple primary cancers: Clinical features of 59 cases and point mutation analyses. PMID: 28599473 Ref: Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations. PMID: 28611205 Ref: Molecular Targeted Drugs and Treatment of Colorectal Cancer: Recent Progress and Future Perspectives. PMID: 28622036 Ref: Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF(V600E) mutant cancer. PMID: 28645859 Ref: BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity. PMID: 28655712 Ref: Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment. PMID: 28708103 Ref: Understanding and Resetting Radiation Sensitivity in Rectal Cancer. PMID: 28742699 Ref: Measurement of Telomere Length in Colorectal Cancers for Improved Molecular Diagnosis. PMID: 28850092 Ref: A guanine derivative as a new MEK inhibitor produced by Streptomyces sp. MK63-43F2. PMID: 28874847 Ref: Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. PMID: 28951457 Ref: Colorectal carcinoma tumour budding and podia formation in the xenograft microenvironment. PMID: 29040282 Ref: Derivation and basic characterization of colorectal carcinoma primary cell lines. PMID: 29042709 Ref: Functional consequence of the p53 codon 72 polymorphism in colorectal cancer. PMID: 29100333 Ref: Lack of microsatellite instability in gastrointestinal stromal tumors. PMID: 29113157 Ref: Current and future biomarkers in colorectal cancer. PMID: 29118555 Ref: miR-422a inhibits cell proliferation in colorectal cancer by targeting AKT1 and MAPK1. PMID: 29118671 Ref: Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine. PMID: 29285234 Ref: EGFR expression in patients with stage III colorectal cancer after adjuvant chemotherapy and on cancer cell function. PMID: 29383110 |
Ref: Targeting RAS signaling pathway as a potential therapeutic target in the treatment of colorectal cancer. PMID: 28262927 Ref: The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer. PMID: 28407239 Ref: Synergistic Antiproliferative Activity of the RAD51 Inhibitor IBR2 with Inhibitors of Receptor Tyrosine Kinases and Microtubule Protein. PMID: 29061656 Ref: HOXA3 promotes tumor growth of human colon cancer through activating EGFR/Ras/Raf/MEK/ERK signaling pathway. PMID: 29073728 Ref: MLK3 phosphorylation by ERK1/2 is required for oxidative stress-induced invasion of colorectal cancer cells. PMID: 29084209 Ref: Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study. PMID: 29129559 Ref: Identification and validation of cetuximab resistance associated long noncoding RNA biomarkers in metastatic colorectal cancer. PMID: 29136952 Ref: Wnt/beta-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer. PMID: 29167314 Ref: RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer. PMID: 29196555 Ref: Fucoidan downregulates insulin-like growth factor-I receptor levels in HT-29 human colon cancer cells. PMID: 29328495 Ref: MiR-142-5p act as an oncogenic microRNA in colorectal cancer: Clinicopathological and functional insights. PMID: 29337244 Ref: Caveolin-1 Inhibits Proliferation, Migration, and Invasion of Human Colorectal Cancer Cells by Suppressing Phosphorylation of Epidermal Growth Factor Receptor. PMID: 29339715 Ref: Baicalin induces cellular senescence in human colon cancer cells via upregulation of DEPP and the activation of Ras/Raf/MEK/ERK signaling. PMID: 29440765 Ref: Correction: Co-targeting translation and proteasome rapidly kills colon cancer cells with mutant RAS/RAF via ER stress. PMID: 29467964 Ref: Phosphorylation of p70 Ribosomal Protein S6 Kinase beta-1 is an Independent Prognostic Parameter in Metastatic Colorectal Cancer. PMID: 29526493 Ref: Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. PMID: 29540830 Ref: BRAF-mutant colorectal cancer, a different breed evolving. PMID: 29708446 Ref: Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome. PMID: 29750335 Ref: Promising New Agents for Colorectal Cancer. PMID: 29752549 Ref: An improved method for culturing patient-derived colorectal cancer spheroids. PMID: 29774115 Ref: Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer. PMID: 29777330 Ref: Efficacy of the MEK Inhibitor Cobimetinib and its Potential Application to Colorectal Cancer Cells. PMID: 29794421 Ref: SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. PMID: 29808006 Ref: AKR1B10 activates diacylglycerol (DAG) second messenger in breast cancer cells. PMID: 29846015 Ref: Erbin Suppresses KSR1-Mediated RAS/RAF Signaling and Tumorigenesis in Colorectal Cancer. PMID: 29980571 Ref: Combination of BEZ235 and Metformin Has Synergistic Effect on Cell Viability in Colorectal Cancer Cells. PMID: 30023463 Ref: Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. PMID: 30042009 Ref: Vemurafenib. PMID: 30069761 Ref: Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer. PMID: 30122982 Ref: Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon. PMID: 30181415 Ref: Comprehensive analysis of differential circular RNA expression in a mouse model of colitis-induced colon carcinoma. PMID: 30182433 Ref: Extracellular galectin-3 facilitates colon cancer cell migration and is related to the epidermal growth factor receptor. PMID: 30210679 Ref: Electrostatic mechanism of V600E mutation-induced B-Raf constitutive activation in colorectal cancer: molecular implications for the selectivity difference between type-I and type-II inhibitors. PMID: 30218115 Ref: Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance. PMID: 30275173 Ref: Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE, a global phase 3 study. PMID: 30339194 Ref: Comprehensive Analysis of the Relationship Between RAS and RAF Mutations and MSI Status of Colorectal Cancer in Northeastern China. PMID: 30359964 Ref: Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data. PMID: 30385823 |